Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828631 | 1.00 | ESR1 (0.49) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL76484 | 0.93 | CYP19A1 (0.53) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL29416717 | 0.93 | CYP19A1 (0.53) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL2322371 | 0.91 | ESR1 (0.58) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL4826058 | 0.91 | CYP19A1 (0.52) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL13513171 | 0.87 | ALDH1A1 (0.49) | ESR1CYP19A1CYP11B2PTGS2 | |
| SCHEMBL2085344 | 0.85 | PTGS2 (0.55) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL13511000 | 0.85 | PTGS2 (0.55) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL2085977 | 0.84 | CYP19A1 (0.45) | ESR1CYP19A1CYP11B2PTGS2ESR2 | |
| SCHEMBL5440826 | 0.84 | CYP19A1 (0.63) | ESR1CYP19A1CYP11B2PTGS2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080193799-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2008-08-14 | — | — | US | disclosed |
| US-7361796-B2 | Orangic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7053255-B2 | Substituted diphenylanthracene compounds for organic electroluminescence devices | IDEMITSU KOSAN CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20060083947-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20040214035-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| EP-1333018-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193799-A1 | Organic electroluminescence device | EED, KCNH2, DCX | ESR1 333/4885CYP19A1 2017/4885CYP11B2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.